MBio Diagnostics is the innovator of the proprietary LightDeck® platform that delivers highly sensitive, on-the-spot lab-quality results in minutes, virtually anywhere. We are developing a robust portfolio of human diagnostics tests internally and collaborate with commercial, academic and government partners.
Our team consists of high-caliber industry veterans, engineers and scientists with expertise in hardware and software development, assay development and manufacturing. Our ISO 13485 certified facilities in Boulder, Colorado include fully equipped biosafety laboratories for assay development and cleanroom for cartridge production.
We are developing a portfolio of diagnostic tests for medical settings where lab-quality results are vital in making time-critical decisions.
The LightDeck COVID-19 Total Antibody Test helps to determine if a person had a past infection.
The LightDeck Host-Response Panels measure biomarkers that appear early in acute infections.
This product line includes point-of-care tests to assess heart attack, heart failure or blood clots in the lungs.
MBio Diagnostics has built strong relationships within government agencies, including BARDA, DARPA, NIH and others. We have been awarded more than $25 million in government contracts to fund feasibility and product development work in COVID screening, host-response and sepsis.
Our commercial collaborations are matched to the partner’s needs. Typical arrangements include initial funded feasibility programs followed by comprehensive product development and manufacturing supply agreements. We provide engineering and assay development expertise, including migrating existing assays to the LightDeck platform and developing novel assays.
Contact us to explore partnership opportunities.